Global Head of DMPK & Modeling
Alison Betts, Takeda
personal info
- Alison has 29 years of experience in the industry, as DMPK, PK/PD and QSP modeling and simulation leader.
- Alison started her career at Pfizer in the UK in 1994 in the department of Drug Metabolism.
- Across her 25 year tenure at Pfizer Alison worked across 3 different sites (Sandwich UK, Groton, CT and Cambridge MA) supporting the discovery and development of many different drug modalities across therapeutic areas. In the last 10 years at Pfizer she led the modeling and simulation group supporting the Oncology research unit. Notable highlights include support of the relaunch of Mylotarg, the approval of Inotuzumab and the discovery of the BCMA-CD3 bispecific mAb.
- After 25 years at Pfizer, Alison started a new role as Vice President of Scientific Collaborations, Fellow of Modeling & Simulation at Applied BioMath in 2019.
- During her time at ABM she was also recipient and Principal Investigator of an NIH SBIR Grant to build a platform QSP model for ADCs (ADC Workbench) capable of predicting efficacy and toxicity with the aim of reducing TI.
- In 2023 Alison joined Takeda as the Global Head of DMPK & Modeling, where she leads scientists across three sites (Boston, San Diego & Japan) in support of a multi-modality portfolio across 3 therapeutic areas (Oncology, GI and Neuroscience).
- In her diverse and extensive modeling and simulation career, Alison has published 31 manuscripts and has given 40 invited presentations at conferences.
- Alison holds a Ph.D. in Systems Pharmacology from the University of Leiden, the Netherlands, and a B.Sc. in Biochemistry from the University of St Andrews